Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

NCT00452140 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped company focus on other projects

Conditions

Metastatic Breast Cancer
Advanced Breast Cancer

Interventions

BIOLOGICAL: ertumaxomab

Sponsor

Neovii Biotech